CRO NACE Rev. 2 46.46 in IE. Official registry identity and a deliberately broad public benchmark curve on one indexed company profile.
A deliberately broad indicative range built from comparable companies with stronger filed or size evidence. It is not a company-specific appraisal, market value, asking price, or offer.
Broad benchmark based on comparable companies in this sector — not a company-specific appraisalOne public valuation range is currently available. A future eligible filing can extend this into a trend.
The historical value curve is public. Create a free account for the future five-year growth outlook, the insights behind it, and concrete action points that can increase this company’s value.
Free account · private workspace
Each step adds evidence that narrows the range. Public filings are a starting point. Connected accounts, owner context and method review make the valuation more useful for real decisions.
Own this company? Claim and manage the profileThis broad public curve is a starting point based on governed sector or size evidence. Create a free account to refine it with verified company data and see the five-year outlook with concrete action points.
Express interest and ask Upswitch to discreetly sound out the owner. We review every request before making contact.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
INTERGAL PHARMA IRELAND LIMITED is a CRO NACE Rev. 2 46.46 based in Ireland. The company was founded in 2018, incorporated as a LTD - Private Company Limited by Shares.
INTERGAL PHARMA IRELAND LIMITED is listed in Irish Companies Registration Office (CRO) under registry number 630239.
Companies in this NACE 46.46 band file annual accounts with CRO.
INTERGAL PHARMA IRELAND LIMITED's public curve tracks a deliberately broad p10-p90 sector benchmark based on at least 30 comparable companies with stronger filed or size evidence. Its centre line is only the arithmetic middle of the published band: not a company-specific appraisal, sale price, offer, or recommendation.
The most recent annual filing covers 2025 (period end 2025-09-30).
If you are researching INTERGAL PHARMA IRELAND LIMITED, this page combines its official registry identity, sector, legal form, location and incorporation or status facts with a deliberately broad peer benchmark.
INTERGAL PHARMA IRELAND LIMITED was founded in 2018 and is registered with Irish Companies Registration Office (CRO), incorporated as a LTD - Private Company Limited by Shares.
INTERGAL PHARMA IRELAND LIMITED is registered under NACE 46.46: CRO NACE Rev. 2 46.46. That places the business within the Irish cluster for this activity.
The most recently filed annual accounts cover fiscal year 2025 (period end 2025-09-30), publicly available via Irish Companies Registration Office (CRO).
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for INTERGAL PHARMA IRELAND LIMITED may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
